Please login to the form below

Not currently logged in
Email:
Password:

Actavis Germany H1 2007 sales increase 21 per cent

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

With Actavis' third party division sales included in the results, total sales in Germany were EUR 66m in H1 FY07. Actavis' largest market is North America, which brought in sales of over EUR 500m in annual sales.

IMS data has also revealed that Actavis Deutschland is the seventh largest generic pharmaceuticals company in Germany, which is also Europe's largest generics market.

Even though market reforms and generic price erosion have reduced the attractiveness of the German market, Actavis has still increased its revenue growth in the region by 21 per cent, compared with H1 FY06 figures. The success has been attributed to Actavis' full product pipeline and sales force of 130 reps, which is set to increase.

The recent preferred partnership contract agreement with Allgemeine Ortskrankenkassen (AOK), Germany's largest General local health insurance provider, has helped ramp up sales. Actavis also provides over 40 products for the VdAK and the AEV insurance associations.

Actavis' deputy CEO, Sigurdur Oli Olafsson, said: "Going forward, we expect to see good growth in our German business, through an increasing number of new product launches, continued alliances with leading German insurance funds, as well as our important partnership arrangements with German generic companies for product supply."

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics